ArticleInternational ophthalmology2025
Can the combination of citicoline and vitamin B12 be beneficial in the healing of corneal nerves after corneal cross-linking?
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effect of topical citicoline, vitamin B12 and hyaluronic acid (OMK2 eye drops; Omikron Italia Srl, Italy) on the healing of corneal nerve after corneal cross-linking (CXL) treatment in patients with keratoconus (KC).
methodsA total of 44 eyes of 22 patients with KC who underwent CXL were included in this prospective study. After CXL, one eye of these patients received OMK2 eye drop and standard post-CXL treatment (OMK2 group), while the fellow eye received only standard post-CXL treatment (control group). The following parameters were analyzed in the pre- and post-CXL procedure periods (1st, 3rd and 6th months): corneal sensitivity, tear film stability, central corneal thickness (CCT), and the corneal sub-basal nerve plexus (sbNP) parameters (including corneal nerve fiber density [CNFD], corneal nerve branch density [CNBD], corneal nerve fiber length [CNFL], corneal total branch density [CTBD], corneal nerve fiber area [CNFA], corneal nerve fiber width [CNFW]).
resultsFollowing CXL, a comparison of the baseline and month 6 data revealed that CNFA decreased in the control group (p < 0.001) and did not differ in the OMK2 group (p = 0.283). Other corneal sbNP parameters exhibited a decrease when comparing baseline and 6 months in each group (all p < 0.05). In addition, CCT in the OMK2 group was not significantly different between baseline and month 6 (p = 0.052). However, a decline in CCT of the control groups was observed during this specified time interval (p = 0.009). Corneal sensitivity or tear film stability parameters did not differ significantly between groups at any time point or over time within each group (all p > 0.05).
conclusionThe use of OMK2 eye drop after CXL may provide more stable CNFA. In addition, it may also provide faster recovery in CCT.
Indexed as
Identifiers
39890769What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.